PITTSBURGH

Matthews International Announces Second Quarter Fiscal 2024 Earnings Release and Conference Call

Retrieved on: 
Monday, April 8, 2024
Corporate development

PITTSBURGH, April 08, 2024 (GLOBE NEWSWIRE) -- Matthews International Corporation (Nasdaq GSM: MATW) today announced plans to release its second quarter fiscal year 2024 earnings results after the market closes on Thursday, May 2, 2024.

Key Points: 
  • PITTSBURGH, April 08, 2024 (GLOBE NEWSWIRE) -- Matthews International Corporation (Nasdaq GSM: MATW) today announced plans to release its second quarter fiscal year 2024 earnings results after the market closes on Thursday, May 2, 2024.
  • The Company will host a conference call and webcast to review the financial and operating results for the period and discuss its outlook.
  • Participating in the call will be Joseph C. Bartolacci, President and CEO, Steven F. Nicola, Chief Financial Officer, and William D. Wilson, Senior Director, Corporate Development.
  • A question-and-answer session will follow.

Pittsburgh Post-Gazette Features One of Zefiro Methane’s Subsidiaries in an Article on Orphaned Wells in Pennsylvania

Retrieved on: 
Friday, April 5, 2024
Carbon, Press, Philosophy, Federation, METHANE, News, Hope, United, Radar, P&G, Water, Environmental Defense Fund, Pharmaceutical industry

FORT LAUDERDALE, Fla., April 05, 2024 (GLOBE NEWSWIRE) -- ZEFIRO METHANE CORP. (the “Company”, “Zefiro”, or “ZEFI”) is pleased to announce that earlier this week, the Pittsburgh Post-Gazette newspaper published an article on opportunities stemming from the orphaned well problem in the state of Pennsylvania, featuring commentary and insights from Plants & Goodwin, Inc. (“Plants & Goodwin” or “P&G”), one of Zefiro’s operating subsidiaries which was acquired by the Company in May 2023. Plants & Goodwin is headquartered in Bradford, Pennsylvania, and also operates in the states of New York, Ohio, and West Virginia.

Key Points: 
  • An untold amount of orphaned oil and gas wells exist in the state of Pennsylvania.
  • Plants & Goodwin is headquartered in Bradford, Pennsylvania, and also operates in the states of New York, Ohio, and West Virginia.
  • Please access the Investors section of the Company’s website for a version of this press release containing all published media.
  • In contrast to legacy ‘ESG’ values, we do not seek to divert capital away from the oil and gas industry.

Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

Retrieved on: 
Friday, April 5, 2024
NMIBC, Patient, Mouse, Cancer, Bladder cancer, LIPO, Pembrolizumab, Society, ASCO, Therapy, Physician

Lipella’s abstract, “Intravesical local administration of pembrolizumab for treatment of bladder cancer: A novel strategy to minimize toxicity” will be published at www.asco.org/abstracts .

Key Points: 
  • Lipella’s abstract, “Intravesical local administration of pembrolizumab for treatment of bladder cancer: A novel strategy to minimize toxicity” will be published at www.asco.org/abstracts .
  • Dr. Jonathan Kaufman, Chief Executive Officer of Lipella, said, “ASCO’s 2024 meeting is the ideal venue for dissemination of our recent progress in the treatment of bladder cancer.
  • Lipella’s new product candidate, LP-50 (intravesical pembrolizumab), is intended to be indicated for non-muscle invasive bladder cancer (NMIBC).
  • Dr. Michael Chancellor, Lipella’s Chief Medical Officer, emphasized the significance of this milestone for advancing the company’s LP-50 program.

Vimeo Appoints Philip Moyer as New Chief Executive Officer

Retrieved on: 
Thursday, April 4, 2024
Cloud, Online, GE Aviation, Microsoft, Google Cloud, Amazon (company), Venture capital, Computer science, General Electric Company, Philip, Financial services, Business development, AI, University of Pittsburgh, University, Software, Engineering, Disclosure, Pete Musser, Alphabet Inc., Capital market, Amazon Web Services, Donnelley Financial Solutions, Creativity, S.A, Martech, Interim, Payment, Management

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Vimeo (NASDAQ: VMEO), the leading video platform for businesses, today announced the appointment of Philip Moyer as Chief Executive Officer and member of the Board of Directors, effective April 8, 2024.

Key Points: 
  • NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Vimeo (NASDAQ: VMEO), the leading video platform for businesses, today announced the appointment of Philip Moyer as Chief Executive Officer and member of the Board of Directors, effective April 8, 2024.
  • Adam Gross, the Company’s Interim Chief Executive Officer and member of the Board, will remain on the Board after the transition.
  • “I’m thrilled to join as CEO of Vimeo, a platform that revolutionizes how millions engage with video content worldwide,” said Moyer.
  • On Monday, May 6, 2024 at 5:00pm ET, Vimeo will live stream a video conference which will include Philip to answer questions regarding its first quarter results.

Carmell Announces $3.0 Million Private Placement

Retrieved on: 
Thursday, April 4, 2024
Private placement, Private, Sale, Skin, Financial services

PITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced that it entered into a securities purchase agreement with new and existing investors for the issuance and sale of approximately 1,333,333 shares of its common stock in a private placement at a price of $2.25 per common share for aggregate gross proceeds of 3 million dollars before deducting offering expenses (the “Private Placement”).

Key Points: 
  • PITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced that it entered into a securities purchase agreement with new and existing investors for the issuance and sale of approximately 1,333,333 shares of its common stock in a private placement at a price of $2.25 per common share for aggregate gross proceeds of 3 million dollars before deducting offering expenses (the “Private Placement”).
  • The Chief Executive Officer of the Company participated in the Private Placement at a price of $2.88 per common share, which was the closing sale price of its common stock on the Nasdaq Capital Market on April 3, 2024.
  • Following the Closing of the Private Placement, Carmell will have approximately 20.58 million common shares outstanding.
  • Brookline Capital Markets, a division of Arcadia Securities, LLC, served as the exclusive placement agent for the private placement transaction.

Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting

Retrieved on: 
Thursday, April 4, 2024
Poster, Annual general meeting, KRYS, Interleukin, AACR

PITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new preclinical data on local and systemic immune activation following intratumoral injection of the Company’s platform technology encoding murine interleukin-12 (IL-12) and interleukin-2 (IL-2), the species matched equivalent to the Company’s clinical-stage oncology product candidate KB707, at the American Association for Cancer Research (AACR) 2024 Annual Meeting being held from April 5-10, 2024 in San Diego, California.

Key Points: 
  • PITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new preclinical data on local and systemic immune activation following intratumoral injection of the Company’s platform technology encoding murine interleukin-12 (IL-12) and interleukin-2 (IL-2), the species matched equivalent to the Company’s clinical-stage oncology product candidate KB707, at the American Association for Cancer Research (AACR) 2024 Annual Meeting being held from April 5-10, 2024 in San Diego, California.
  • Poster presentation details are as follows:
    The poster will be available to conference attendees.
  • Following the presentation, the poster will also be available to view online on the Investor section of the Company’s website .

Greater Pittsburgh Festival of Books Releases Author Lineup, Opens Registration

Retrieved on: 
Wednesday, April 3, 2024
Storm, Carnegie library, Festival, HuffPost, Fordham University, Love, Acclamation, National Magazine Awards, Education Week, USA Today, The New York Times, English, Caregiver, Social justice, Barack Obama Academy, PBS, Black, Magic, Child, University, University of Pittsburgh, Teachers College, Columbia University, Perfect storm, Poetry, Diving, Carnegie Library of Pittsburgh, Catalog, Book, Death, KDKA, NPR, News Hour, Film industry

Pittsburgh, April 03, 2024 (GLOBE NEWSWIRE) -- Today, the Greater Pittsburgh Festival of Books announced registration is open for its third annual event, happening on May 11, 2024 on the campus of the Pittsburgh Theological Seminary in East Liberty.

Key Points: 
  • Pittsburgh, April 03, 2024 (GLOBE NEWSWIRE) -- Today, the Greater Pittsburgh Festival of Books announced registration is open for its third annual event, happening on May 11, 2024 on the campus of the Pittsburgh Theological Seminary in East Liberty.
  • Specially planned this year, the event will focus a portion of its programming on stories about Pittsburgh – and the greater Pittsburgh area – by hometown authors.
  • The Festival will be held from 10 a.m. to 5 p.m. on Saturday, May 11 at 616 North Highland Avenue, Pittsburgh.
  • The Festival is made possible thanks to support from sponsors including Carnegie Library of Pittsburgh, The Jack Buncher Foundation, KDKA and others.

Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis

Retrieved on: 
Wednesday, April 3, 2024
Urinalysis, Type, HC, Patient, History, Tacrolimus, Urine, Ifosfamide, Nephrology, Breast cancer, Hemorrhagic cystitis, Safety, FDA, Cyclophosphamide, Food, Pharmaceutical industry

Lipella expects to meet with the FDA on May 21, 2024.

Key Points: 
  • Lipella expects to meet with the FDA on May 21, 2024.
  • HC is a serious, life-threatening form of gross hematuria (i.e.
  • Lipella published these results in the peer-reviewed journal, International Urology and Nephrology , in September 2023, and received preliminary guidance from the FDA regarding potential registration endpoints.
  • The company’s anticipated Type C meeting with the FDA will focus on reaching an agreement for the proposed Phase-2b trial design, which Lipella expects to be a 36-subject, prospective, double-blind, placebo-controlled study with a primary efficacy assessment derived from the reduction in patient-reported frequency of gross hematuria episodes over a seven-day period.

Lynch Carpenter Investigates Claims in AT&T Data Breach

Retrieved on: 
Tuesday, April 2, 2024
Name, Social Security, Social, LLP, AT&T

PITTSBURGH, April 02, 2024 (GLOBE NEWSWIRE) -- AT&T recently confirmed that the personal information of millions of current and former account holders has been leaked online.

Key Points: 
  • PITTSBURGH, April 02, 2024 (GLOBE NEWSWIRE) -- AT&T recently confirmed that the personal information of millions of current and former account holders has been leaked online.
  • The information potentially impacted includes current and former AT&T customer information, including names, email addresses, mailing addresses, phone numbers, Social Security numbers, dates of birth, AT&T account numbers, and AT&T account passcodes.
  • Lynch Carpenter, LLP is investigating claims against AT&T related to this data compromise.
  • If you received a data breach notification from AT&T, you may be entitled to compensation.

Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 28, 2024
Consultant, CRH, Ovarian cancer, Conference call, Conference, Survival, Science, Intelligence, Drug discovery, Webcast, BIO, Research, Holocene, UPMC, KOL, G&A, Call, GMP, UPMC Magee-Womens Hospital, Cloud computing, CLIA, Drug development, Machine learning, Marketing, Artificial intelligence, Cryptocurrency

The company reported a net loss of approximately $14 million on total revenue of approximately $1.8 million for the year ended December 31, 2023.

Key Points: 
  • The company reported a net loss of approximately $14 million on total revenue of approximately $1.8 million for the year ended December 31, 2023.
  • “Perhaps most notably, we announced last quarter that we successfully delivered the results of our first campaign with Cancer Research Horizons.
  • Revenues for the years ended December 31, 2023, and December 31, 2022, were primarily derived from its Eagan operating segment.
  • Conference call and webcast details:
    Predictive Oncology management will host an investor conference call and webcast on Monday, April 1st, at 8:30am EDT.